文献速递主动脉疾病

Nellix内移植物腔内动脉瘤封堵术后长期失败的单中心真实世界经验

Long-term failure after endovascular aneurysm sealing in a real-life, single-center experience with the Nellix endograft.
PubMed 文献 · J Vasc Surg · 2020-12-02

该单中心回顾性研究纳入2013至2018年接受择期EVAS治疗肾下腹主动脉瘤的101例患者,中位随访45个月。结果显示治疗失败率30.7%,二次破裂率6.9%,免于再干预率随时间下降至6年52.1%,且失败率在2016版IFU内外无显著差异。

要点

  • EVAS术后治疗失败率高达30.7%,中位失败时间34个月。
  • 免于再干预率1年94.7%、4年77%、6年52.1%,随时间显著下降。
  • 2016版IFU内外亚组失败率无显著差异,提示解剖参数不影响失败风险。

核心结论

  • EVAS在多个关键终点上表现劣于传统腔内移植物,且不受术前解剖参数影响。
  • 治疗失败发生率随时间推移呈增加趋势,尤其在术后4年后更为明显。

研究设计与样本

  • 单中心回顾性队列研究,纳入2013至2018年择期接受EVAS治疗肾下腹主动脉瘤的101例患者。
  • 中位随访45个月(3.75年),按2016版IFU回顾性再分类。

主要发现

  • 治疗失败见于101例中的31例(30.7%),中位失败间隔34个月。
  • 6.9%的患者发生二次破裂。
  • 免于动脉瘤相关死亡1年与2年均为96.9%,5年为89.9%。
  • 免于再干预1年94.7%、4年77%、6年52.1%。
  • 14例(13.9%)接受了急诊或择期移植物取出。

关键数值与推荐

  • 治疗失败定义:移植物迁移>5 mm、瘤囊扩张>5 mm、IA型内漏(Van den Ham分类Is2和Is3)、Ib型内漏及二次破裂。

临床怎么用

  • EVAS术后需长期密切影像随访,尤其关注术后4年后的失败风险。
  • 对于接受EVAS的患者,应警惕二次破裂及再干预需求,及时评估移植物取出指征。

局限性

  • 单中心回顾性设计,样本量有限(101例),可能存在选择偏倚。
  • 随访时间中位45个月,部分患者随访时间不足以评估更远期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovascular aneurysm sealing (EVAS) is an innovative alternative to conventional endovascular aneurysm repair (EVAR). EVAS relies on sac anchoring without proximal fixation to achieve sealing and should have allowed for the treatment of a broader range of anatomic features compared with standard EVAR. Despite the encouraging early reports, the mid- and long-term follow-up data have shown increased rates of failure. To address the issue, the manufacturer introduced revised instructions for use (IFU) in 2016. The present study reports the outcomes of this system after a median follow-up of 45 months. METHODS: Data for all patients electively treated with EVAS at our institution were retrospectively collected. The patients were retrospectively reclassified according to the 2016 revised IFU of the device. All patients in the present series had undergone EVAS for the treatment of infrarenal abdominal aortic aneurysms (AAAs). The primary end point was therapeutic failure: graft migration >5 mm, sac expansion >5 mm, type IA endoleak (Is2 and Is3 using the Van den Ham classification), type Ib endoleak, and secondary rupture. The overall mortality, aortic-related mortality, and reintervention rates were also analyzed. RESULTS: A total of 101 patients had undergone elective treatment by EVAS from 2013 to 2018 for infrarenal AAAs. The median follow-up was 3.75 years. Therapeutic failure was observed in 31 of the 101 patients (30.7%), with no significant difference between the in-IFU and off-IFU 2016 subgroups. Failure occurred at a median interval of 34 months from the index procedure. Of the 101 patients, 6.9% had presented with secondary rupture. Freedom from aneurysm-related mortality was 96.9% at 1 and 2 years and 89.9% at 5 years. Freedom from reintervention decreased over time: 94.7% at 1 year, 77% at 4 years, and 52.1% at 6 years. Of the 101 patients, 14 (13.9%) had undergone emergent or elective graft explantation. CONCLUSIONS: EVAS performed worse than conventional endografts for several critical end points, regardless of any preoperative anatomic parameters. The incidence of therapeutic failures tended to increase over time, especially 4 years after the index procedure.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Quaglino S, Mortola L, Ferrero E, et al. Long-term failure after endovascular aneurysm sealing in a real-life, single-center experience with the Nellix endograft. J Vasc Surg. 2020. PMID: 33278539. doi:10.1016/j.jvs.2020.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。